Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome.
Badawy, Abdulla A-B, Morgan, Christopher J, Llewelyn, Meirion B et al. · Journal of psychopharmacology (Oxford, England) · 2005 · DOI
Quick Summary
Researchers measured levels of tryptophan (a building block for serotonin, a brain chemical) in 23 people with ME/CFS and 42 healthy controls. They observed that people with ME/CFS had higher levels of free tryptophan available to the brain compared to controls. The study also identified two possible subgroups within the ME/CFS patients—one with normal serotonin status and one with elevated serotonin status. However, this is a single cross-sectional study, and the clinical significance of these differences remains unclear.
Why It Matters
Tryptophan availability influences brain serotonin synthesis and may be relevant to fatigue, mood, and cognitive symptoms reported in ME/CFS. The observation of heterogeneity in serotonin status aligns with growing evidence that ME/CFS comprises distinct biological subgroups, which could inform future targeted investigation of neurochemical mechanisms and potential therapeutic approaches.
Observed Findings
Free tryptophan–to–competing amino acid ratio was 43% higher in ME/CFS patients compared to controls, associated with 48% higher free serum tryptophan concentration.
Total serum tryptophan concentration was 19% higher in ME/CFS patients; when co-varied with age and gender, the total tryptophan–to–competing amino acid ratio also differed significantly.
Competing amino acid concentrations were not significantly different between groups overall but were significantly lower in females than males within the ME/CFS patient group.
Two provisional serotonin-status subgroups were identified within the ME/CFS cohort: one with normal serotonin status and one with elevated serotonin status.
Inferred Conclusions
The authors propose that altered tryptophan availability to the brain may reflect heterogeneity in serotonin-biosynthetic status among ME/CFS patients, suggesting that serotonin metabolism is a candidate area for stratified investigation.
The authors suggest that their findings have implications for pharmacological and other therapies of ME/CFS, though specific therapeutic recommendations are not detailed in the abstract.
The authors conclude that sex differences in competing amino acid levels may influence tryptophan availability differently in male and female ME/CFS patients.
Remaining Questions
Is the observed elevation in free tryptophan associated with specific ME/CFS symptom clusters or disease severity?
What This Study Does Not Prove
This study does not establish that altered tryptophan availability causes ME/CFS symptoms or that it is a primary driver of disease pathology. The cross-sectional design cannot determine whether the observed differences in tryptophan are a consequence of ME/CFS, a contributing factor, or an epiphenomenon. The findings do not constitute evidence for or against any specific treatment and do not address whether normalising tryptophan availability would improve clinical outcomes.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.